| Patient Demographics (N = 356) . | . |
|---|---|
| . | Median [IQR], N (%) . |
| Age | 55 [41-65] |
| Gender | 186 (52.2%) Female |
| Race | |
| White | 284 (79.8%) |
| Black | 18 (5.1%) |
| Asian | 15 (4.2%) |
| American Indian/Alaskan Native | 2 (0.5%) |
| Other | 22 (6.2%) |
| Declined | 15 (4.2%) |
| Ethnicity | |
| Hispanic | 25 (7.0%) |
| Non-Hispanic | 314 (88.2%) |
| Declined | 17 (4.8%) |
| Tumor | |
| Primary CNS tumors | 313 (87.9%) |
| Metastatic tumors | 43 (12.1%) |
| TRE | 199 (55.9%) |
| Tumor status in patients with TRE | |
| Initial diagnosis and early treatment | 70 (35.2%) |
| Stable or regression | 85 (42.7%) |
| Progression | 44 (22.1%) |
| Patient Demographics (N = 356) . | . |
|---|---|
| . | Median [IQR], N (%) . |
| Age | 55 [41-65] |
| Gender | 186 (52.2%) Female |
| Race | |
| White | 284 (79.8%) |
| Black | 18 (5.1%) |
| Asian | 15 (4.2%) |
| American Indian/Alaskan Native | 2 (0.5%) |
| Other | 22 (6.2%) |
| Declined | 15 (4.2%) |
| Ethnicity | |
| Hispanic | 25 (7.0%) |
| Non-Hispanic | 314 (88.2%) |
| Declined | 17 (4.8%) |
| Tumor | |
| Primary CNS tumors | 313 (87.9%) |
| Metastatic tumors | 43 (12.1%) |
| TRE | 199 (55.9%) |
| Tumor status in patients with TRE | |
| Initial diagnosis and early treatment | 70 (35.2%) |
| Stable or regression | 85 (42.7%) |
| Progression | 44 (22.1%) |
Abbreviations: CNS, central nervous system; IQR, interquartile range; TRE: tumor-related epilepsy.
| Patient Demographics (N = 356) . | . |
|---|---|
| . | Median [IQR], N (%) . |
| Age | 55 [41-65] |
| Gender | 186 (52.2%) Female |
| Race | |
| White | 284 (79.8%) |
| Black | 18 (5.1%) |
| Asian | 15 (4.2%) |
| American Indian/Alaskan Native | 2 (0.5%) |
| Other | 22 (6.2%) |
| Declined | 15 (4.2%) |
| Ethnicity | |
| Hispanic | 25 (7.0%) |
| Non-Hispanic | 314 (88.2%) |
| Declined | 17 (4.8%) |
| Tumor | |
| Primary CNS tumors | 313 (87.9%) |
| Metastatic tumors | 43 (12.1%) |
| TRE | 199 (55.9%) |
| Tumor status in patients with TRE | |
| Initial diagnosis and early treatment | 70 (35.2%) |
| Stable or regression | 85 (42.7%) |
| Progression | 44 (22.1%) |
| Patient Demographics (N = 356) . | . |
|---|---|
| . | Median [IQR], N (%) . |
| Age | 55 [41-65] |
| Gender | 186 (52.2%) Female |
| Race | |
| White | 284 (79.8%) |
| Black | 18 (5.1%) |
| Asian | 15 (4.2%) |
| American Indian/Alaskan Native | 2 (0.5%) |
| Other | 22 (6.2%) |
| Declined | 15 (4.2%) |
| Ethnicity | |
| Hispanic | 25 (7.0%) |
| Non-Hispanic | 314 (88.2%) |
| Declined | 17 (4.8%) |
| Tumor | |
| Primary CNS tumors | 313 (87.9%) |
| Metastatic tumors | 43 (12.1%) |
| TRE | 199 (55.9%) |
| Tumor status in patients with TRE | |
| Initial diagnosis and early treatment | 70 (35.2%) |
| Stable or regression | 85 (42.7%) |
| Progression | 44 (22.1%) |
Abbreviations: CNS, central nervous system; IQR, interquartile range; TRE: tumor-related epilepsy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
